Evaluation of Gabapentin as a Treatment of Breakthrough Cancer Pain Caused by Metastatic Prostate Adenocarcinoma

Figures & data

Table 1 Characteristics of Patients with BTcP Caused by Metastatic Prostate Adenocarcinoma

Characteristics	n	%
Age (Years)
46–55	3	13.0
56–65	7	30.4
>65	13	56.6
Drug Type
Gabapentin	11	47.8
Gabapentin + Opioid	12	52.2
Type of Pain (PainDETECT)
Neuropathic	0	0
Nociceptive	0	0
Mixed pain	30	100

Table 2 Pain Reduction in Each Anti-Pain Group

Gabapentin	Mean	Pain Reduction	p
Pretreatment (H1-H2)	8,3
Posttreatment (H3-H4)	6.1	2.2	<0.001
Posttreatment (H5-H6)	4.2	2.1	<0.001
Gabapentin + Opioid	Mean	Pain Reduction	p
Pretreatment (H1-H2)	7.7
Posttreatment (H3-H4)	5.7	2.0	<0.001
Posttreatment (H5-H6)	4,5	1.2	<0.001

Table 3 Comparison of Pain Reduction for Each Antipain Group

Day	Treatment	Initial Pain	Mean	Pain Reduction	p
3–4	Gabapentin	8,3	6.1	2.2	0.542
	Gabapentin + Opioids	7.7	5.7	1.9
Day	Treatment	Initial Pain	Mean	Pain Reduction	p
5–6	Gabapentin	8,3	4.2	4.1	0.151
	Gabapentin + Opioids	7.7	4,5	3.2